Search | Clinical Trials Finder

Conditions: Anemia, Lung Cancer
Interventions: methoxy polyethylene glycol epoetin beta; Biological
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Docetaxel, Gemcitabine, Gemcitabine Hydrochloride, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Ramucirumab; Drug · Biological
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 889
States / cities: Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 593 more

Conditions: Non-small Cell Lung Cancer
Interventions: LYC-55716, Pembrolizumab; Drug
Lead sponsor: Lycera Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Aurora, Colorado • Ann Arbor, Michigan • Nashville, Tennessee + 1 more

Conditions: Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions: Paclitaxel, Carboplatin, STA 4783; Drug
Lead sponsor: Synta Pharmaceuticals Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 19
States / cities: Jonesboro, Arkansas • Pomona, California • San Francisco, California + 15 more

Conditions: Non-Squamous Non-Small Cell Lung Cancer
Interventions: Placebo, RO5490258, bevacizumab [Avastin], cisplatin/carboplatin, paclitaxel, pemetrexed; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 32
States / cities: Huntsville, Alabama • Scottsdale, Arizona • Bakersfield, California + 27 more

Conditions: Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, HER2 Exon 20 Mutations, EGFR Exon 20 Mutations, EGFR Uncommon Mutations, Including G719X and S768I
Interventions: Furmonertinib; Drug
Lead sponsor: ArriVent BioPharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 7
States / cities: Prescott, Arizona • Sacramento, California • Whittier, California + 4 more

Conditions: Non-small Cell Lung Cancer
Interventions: Necitumumab, Gemcitabine, Cisplatin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Birmingham, Alabama • Deerfield Beach, Florida • Farmington Hills, Michigan

Conditions: Non-small Cell Lung Cancer
Interventions: DS-1062a, Docetaxel; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 605 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 32
States / cities: Chandler, Arizona • Anaheim, California • Glendale, California + 28 more

Conditions: Non Small Cell Lung Cancer
Interventions: LY2603618, Pemetrexed; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 9
States / cities: Tucson, Arizona • Denver, Colorado • Tampa, Florida + 6 more

Conditions: Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Oligoprogressive Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Computed Tomography, Copper Cu 64-DOTA-pembrolizumab, Low Dose Radiation Therapy, Pembrolizumab, Positron Emission Tomography, Stereotactic Body Radiation Therapy; Procedure · Radiation · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Metastatic Non Small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer
Interventions: Etirinotecan pegol (NKTR-102); Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma
Interventions: Cobimetinib, GDC-0994; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Aurora, Colorado • New Haven, Connecticut • Boston, Massachusetts + 2 more

Conditions: Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer
Interventions: CI-1040; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Bevacizumab, Brigatinib; Biological · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 6
States / cities: Duarte, California • Aurora, Colorado • Chicago, Illinois + 2 more

Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions: Clinical Observation, External Beam Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Standard Follow-Up Care, Therapeutic Conventional Surgery; Other · Radiation · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 2
States / cities: Denver, Colorado • Houston, Texas

Conditions: Non-Small Cell Lung Cancer
Interventions: L-DOS47; Drug
Lead sponsor: Helix BioPharma Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Cleveland, Ohio • Houston, Texas

Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions: Laboratory Biomarker Analysis, Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Other · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 12
States / cities: Anchorage, Alaska • Bozeman, Montana • Kennewick, Washington + 7 more

Conditions: Non-Small Cell Lung Cancer, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation
Interventions: STX-721/PFL-721 (Escalated), STX-721/PFL-721 (3 dose levels), STX-721/PFL-721 (RP2D); Drug
Lead sponsor: Pierre Fabre Medicament; Industry
Eligibility: 18 Years and older
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 9
States / cities: Duarte, California • Huntington Beach, California • Irvine, California + 6 more

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions: Computed Tomography, Fractionated Stereotactic Radiation Therapy, Magnetic Resonance Imaging, Stereotactic Radiosurgery; Procedure · Radiation
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 262
States / cities: Tucson, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 189 more

Conditions: Non-small Cell Lung Cancer
Interventions: Induction chemotherapy and concurrent radiation, Consolidation: Radiation therapy to metastatic sites; Other
Lead sponsor: Leo W. Jenkins Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: Lung Cancer
Interventions: bevacizumab, carboplatin, chemoprotection, paclitaxel, radiation therapy; Biological · Drug · Radiation
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 5
States / cities: Birmingham, Alabama • Chicago, Illinois • Evanston, Illinois + 2 more

Conditions: Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer, Lung Cancer, Pain, Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions: assessment of therapy complications, cognitive assessment, psychosocial assessment and care; Procedure
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 2,310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 32
States / cities: Chicago, Illinois • Evanston, Illinois • Elkhart, Indiana + 19 more

Conditions: Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Hodgkin Disease, Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Melanoma, Neoplasm Metastasis, Neoplasms, Head and Neck, Neoplasms, Squamous Cell, Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma, Squamous Cell Cancer, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Neoplasm, Lymphoma, Non-Hodgkin, Pancreatic Adenocarcinoma
Interventions: Intravenous (IV) SEA-CD40, Pembrolizumab, Subcutaneous (SC) SEA-CD40, Gemcitabine, Nab-paclitaxel; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 19
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 15 more

Conditions: Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma, Pancreatic Adenocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Stage III Pancreatic Cancer, Stage IIIA Gallbladder Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Gallbladder Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Gallbladder Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Pancreatic Cancer, Unresectable Gallbladder Carcinoma, Unresectable Pancreatic Cancer
Interventions: Cisplatin, Docetaxel, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Pharmacological Study, Recombinant EphB4-HSA Fusion Protein; Drug · Other · Biological
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 2
States / cities: Los Angeles, California • Newport Beach, California

Search by objective public record fields.

Ro 50-3821 in Treating Anemia in Patients Receiving Antineoplastic Therapy for Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer

STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

A Study of Advanced or Metastatic Non-small Cell Lung Cancer

A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab

Etirinotecan Pegol (NKTR-102) in NSCLC

A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors

CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer

Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC

Surgery and/or Radiation Therapy or Standard Therapy and/or Clinical Observation in Treating Patients With Previously Treated Stage IV Non-small Cell Lung Cancer

A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

Treating NSCLC Minimal Stage IV With Curative Intent

Radiation Therapy, Chemotherapy, and Bevacizumab in Treating Patients With Recurrent, Unresectable or Stage III or Stage IV Non-Small Cell Lung Cancer

Study of Symptoms Caused by Cancer and Cancer Therapy in Patients With Invasive Breast, Lung, Prostate, or Colorectal Cancer

Safety Study of SEA-CD40 in Cancer Patients

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors